Understanding what oncologists need for their patients and their clinics

The current oncology pipeline: development and launch

Exceptional launch activity increases options for patients but requires a greater understanding of the impact on treatment pathways and patient segments for payers and clinicians.

Key:
- Targeted
- Immuno-oncology
- Chemotherapy
- Vaccine
- Oncolytic Virus
- Other
- Total Clinical Activity

These figures are estimates based on phase III completion dates. The actual number of launches will depend on successful trial completion and FDA approval. Products in phase II that could successfully move through launch are not included.

The pipeline of oncology drugs in clinical development has expanded by more than 60% between 2005-2015.

Nearly 600 new molecules were in late-stage clinical development in 2019.

The biggest need when introducing a new cancer therapy to clinic:
- Need to understand clinical benefits and patient outcomes (58%)
- Need to assess the therapies’ place in the clinical pathway and treatment guidelines (21%)

What are patient’s biggest concerns apart from survival when initiating a new treatment regime?
- Impact on patient lives (e.g., work and lifestyle activities) (21%)
- Side effects (56%)

What services are most valuable to oncologists and their patients?
- Say the provision of education/support about the new drug (50%)
- Ask for face to face nursing support to train/educate patients (23%)

We understand that you navigate a complex environment when introducing a new cancer therapy to oncologists. Discover how we can design a tailored approach to help you meet your goals.

- Market access strategic consultancy
- Research and insights generation
- MSL training and deployment
- Clinical nurse educators
- Pathway redesign
- Multichannel patient engagement programs